|
1
|
Ben Q, Cai Q, Li Z, Yuan Y, Ning X, Deng S
and Wang K: The relationship between new-onset diabetes mellitus
and pancreatic cancer risk: a case-control study. Eur J Cancer.
47:248–254. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Murray T, Xu J,
Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin.
56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Esposito K, Chiodini P, Colao A, Lenzi A
and Giugliano D: Metabolic syndrome and risk of cancer: a
systematic review and meta-analysis. Diabetes Care. 35:2402–2411.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Unger RH and Orci L: Paracrinology of
islets and the paracrinopathy of diabetes. Proc Natl Acad Sci USA.
107:16009–16012. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stumvoll M, Goldstein BJ and van Haeften
TW: Type 2 diabetes: principles of pathogenesis and therapy.
Lancet. 365:1333–1346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Burney S, Irfan K, Saif MW and Masud F:
Diabetes and pancreatic cancer. JOP. 15:319–321. 2014.PubMed/NCBI
|
|
7
|
Fokas E, O'Neill E, Gordon-Weeks A,
Mukherjee S, McKenna WG and Muschel RJ: Pancreatic ductal
adenocarcinoma: from genetics to biology to radiobiology to
oncoimmunology and all the way back to the clinic. Biochim Biophys
Acta. 1855:61–82. 2015.PubMed/NCBI
|
|
8
|
Walter U, Kohlert T, Rahbari NN, Weitz J
and Welsch T: Impact of preoperative diabetes on long-term survival
after curative resection of pancreatic adenocarcinoma: a systematic
review and meta-analysis. Ann Surg Oncol. 21:1082–1089. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sahin IH, Shama MA, Tanaka M, Abbruzzese
JL, Curley SA, Hassan M and Li D: Association of diabetes and
perineural invasion in pancreatic cancer. Cancer Med. 1:357–362.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nakai Y, Isayama H, Sasaki T, Mizuno S,
Sasahira N, Kogure H, Kawakubo K, Yamamoto N, Hirano K, Ijichi H,
et al: Clinical outcomes of chemotherapy for diabetic and
nondiabetic patients with pancreatic cancer: better prognosis with
statin use in diabetic patients. Pancreas. 42:202–208. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vickers MM, Powell ED, Asmis TR, Jonker
DJ, Hilton JF, O'Callaghan CJ, Tu D, Parulekar W and Moore MJ:
Comorbidity, age and overall survival in patients with advanced
pancreatic cancer - results from NCIC CTG PA.3: a phase III trial
of gemcitabine plus erlotinib or placebo. Eur J Cancer.
48:1434–1442. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chari ST, Leibson CL, Rabe KG, Timmons LJ,
Ransom J, de Andrade M and Petersen GM: Pancreatic
cancer-associated diabetes mellitus: prevalence and temporal
association with diagnosis of cancer. Gastroenterology. 134:95–101.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li J, Cao G, Ma Q, Liu H, Li W and Han L:
The bidirectional interation between pancreatic cancer and
diabetes. World J Surg Oncol. 10:1712012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li D, Mao Y, Chang P, Liu C, Hassan MM,
Yeung SJ and Abbruzzese JL: Impacts of new-onset and long-term
diabetes on clinical outcome of pancreatic cancer. Am J Cancer Res.
5:3260–3269. 2015.PubMed/NCBI
|
|
15
|
Bosetti C, Rosato V, Li D, Silverman D,
Petersen GM, Bracci PM, Neale RE, Muscat J, Anderson K, Gallinger
S, et al: Diabetes, antidiabetic medications, and pancreatic cancer
risk: an analysis from the International Pancreatic Cancer
Case-Control Consortium. Ann Oncol. 25:2065–2072. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mizuno S, Nakai Y, Isayama H, Yanai A,
Takahara N, Miyabayashi K, Yamamoto K, Kawakubo K, Mohri D, Kogure
H, et al: Risk factors and early signs of pancreatic cancer in
diabetes: screening strategy based on diabetes onset age. J
Gastroenterol. 48:238–246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li D, Tang H, Hassan MM, Holly EA, Bracci
PM and Silverman DT: Diabetes and risk of pancreatic cancer: a
pooled analysis of three large case-control studies. Cancer Causes
Control. 22:189–197. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oberaigner W, Ebenbichler C, Oberaigner K,
Juchum M, Schönherr HR and Lechleitner M: Increased cancer
incidence risk in type 2 diabetes mellitus: results from a cohort
study in Tyrol/Austria. BMC Public Health. 14:10582014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu Y, García Rodríguez LA, Malgerud L,
González-Pérez A, Martín-Pérez M, Lagergren J and Bexelius TS:
New-onset type 2 diabetes, elevated HbA1c, anti-diabetic
medications, and risk of pancreatic cancer. Br J Cancer.
113:1607–1614. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang F, Gupta S and Holly EA: Diabetes
mellitus and pancreatic cancer in a population-based case-control
study in the San Francisco Bay Area, California. Cancer Epidemiol
Biomarkers Prev. 15:1458–1463. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Choi Y, Kim TY, Oh DY, Lee KH, Han SW, Im
SA, Kim TY and Bang YJ: The impact of diabetes mellitus and
metformin treatment on survival of patients with advanced
pancreatic cancer undergoing chemotherapy. Cancer Res Treat.
48:171–179. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wolpin BM, Bao Y, Qian ZR, Wu C, Kraft P,
Ogino S, Stampfer MJ, Sato K, Ma J, Buring JE, et al:
Hyperglycemia, insulin resistance, impaired pancreatic β-cell
function, and risk of pancreatic cancer. J Natl Cancer Inst.
105:1027–1035. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sadr-Azodi O, Gudbjörnsdottir S and Ljung
R: Pattern of increasing HbA1c levels in patients with diabetes
mellitus before clinical detection of pancreatic cancer - a
population-based nationwide case-control study. Acta Oncol.
54:986–992. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dandona M, Linehan D, Hawkins W, Strasberg
S, Gao F and Wang-Gillam A: Influence of obesity and other risk
factors on survival outcomes in patients undergoing
pancreaticoduodenectomy for pancreatic cancer. Pancreas.
40:931–937. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cannon RM, LeGrand R, Chagpar RB, Ahmad
SA, McClaine R, Kim HJ, Rupp C, Cho CS, Brinkman A, Weber S, et al:
Multi-institutional analysis of pancreatic adenocarcinoma
demonstrating the effect of diabetes status on survival after
resection. HPB Oxf. 14:228–235. 2012. View Article : Google Scholar
|
|
26
|
van de Poll-Franse LV, Houterman S,
Janssen-Heijnen ML, Dercksen MW, Coebergh JW and Haak HR: Less
aggressive treatment and worse overall survival in cancer patients
with diabetes: a large population based analysis. Int J Cancer.
120:1986–1992. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mao Y, Tao M, Jia X, Xu H, Chen K, Tang H
and Li D: Effect of diabetes mellitus on survival in patients with
pancreatic cancer: a systematic review and meta-analysis. Sci Rep.
5:171022015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Elisei R, Lorusso L, Romei C, Bottici V,
Mazzeo S, Giani C, Fiore E, Torregrossa L, Insilla AC, Basolo F, et
al: Medullary thyroid cancer secreting carbohydrate antigen 19-9
(Ca 19-9): a fatal case report. J Clin Endocrinol Metab.
98:3550–3554. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pall M, Iqbal J, Singh SK and Rana SV: CA
19-9 as a serum marker in urothelial carcinoma. Urol Ann. 4:98–101.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Biadgo B and Abebe M: Type 2 diabetes
mellitus and its association with the risk of pancreatic
carcinogenesis: a review. Korean J Gastroenterol. 67:168–177. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guillaumond F, Leca J, Olivares O, Lavaut
MN, Vidal N, Berthezène P, Dusetti NJ, Loncle C, Calvo E, Turrini
O, et al: Strengthened glycolysis under hypoxia supports tumor
symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma.
Proc Natl Acad Sci USA. 110:3919–3924. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rajeshkumar NV, Dutta P, Yabuuchi S, de
Wilde RF, Martinez GV, Le A, Kamphorst JJ, Rabinowitz JD, Jain SK,
Hidalgo M, et al: Therapeutic targeting of the Warburg effect in
pancreatic cancer relies on an absence of p53 function. Cancer Res.
75:3355–3364. 2015. View Article : Google Scholar : PubMed/NCBI
|
